One-line thesis. Johnson & Johnson is a fortress: AAA-caliber balance sheet, 0.26 beta, 69% gross margin, two diversified franchises (Innovative Medicine + MedTech), and a raised FY26 outlook — but after a +69% twelve-month run it trades at 30× trailing / 22.7× forward for only mid-single-digit revenue growth, so at $263 you are paying a full price for safety and steady ~10% EPS compounding, not for upside. Watch — a quality name to own on a pullback, not to chase at the high.
◆ Synthos call — HoldJNJ is a solid business largely reflected at ~$258 — fine to keep, no reason to chase; it gets interesting again below ~$219.
Downside Risk (lower = safer)
4/10 · Moderate
Fortress balance sheet (net-debt/EBITDA 1.0×), beta 0.26, but 30× trailing after a +69% run and unresolved talc litigation.
Growth Quality
5/10 · Moderate
Only ~7% fwd revenue / ~10% fwd EPS CAGR, but 69% gross margin, 26% ROE, and a durable diversified moat.
Exponential Potential
2/10 · Low
A $633B mega-cap growing mid-single-digits — no acceleration and no room to multibag; steady compounder, not exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 16%/yrTo justify today’s $263, earnings would have to compound roughly 16% a year for 10 years (9% discount rate). Analysts forecast ~15%/yr, so the market is pricing in about what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Johnson & Johnson makes prescription drugs (cancer, immune, brain and heart medicines) and medical devices (surgery tools, heart-rhythm gear, orthopedic implants, vision products). It sold the Band-Aid/Tylenol consumer business off in 2023, so today it is a drug-and-device company, not the household-products company your grandparents knew.
Is the stock cheap or expensive? Expensive-ish. The price jumped almost 70% in the past year and now sits at its highest level ever. You are paying about 30 dollars for every 1 dollar of yearly profit — a full price for a company that only grows sales by mid-single-digit percentages. It is a very safe, very profitable business, but you are not getting it on sale.
Our verdict is Watch: a great, sturdy company, but wait for a better price rather than chase it here.
Here is what our three scores mean in everyday terms:
Downside Risk 4/10 (fairly safe). The company has almost no debt problem, pays a reliable dividend, and its stock barely wobbles. The main worries are the high price and the long-running baby-powder lawsuits.
Growth Quality 5/10 (solid, not spectacular). Extremely profitable and durable, but it grows slowly — think steady oak tree, not a rocket.
Exponential Potential 2/10 (low). It is already one of the biggest companies on earth and grows in single digits, so do not expect it to double quickly.
The one big worry: the decades-old talc/baby-powder lawsuits still are not fully settled, and one of its big drugs (Stelara) is now facing cheap copycats that are eating into sales.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = JNJ · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$263.04
Market cap$633B
P/E trailing11×
P/E FY26E / FY27E23× / 21×
EV / Sales6.9×
EV / EBITDA19.9×
Gross margin69.1%
Net margin21.8%
Dividend yield1.99%
Beta0.256
52-wk range$155 – $263
RSI(14)71
50 / 200-DMA$233 / $219
12-mo return+69% (SPY +21%)
Street target$253 ($208–$283)
Analyst grades21 Buy · 16 Hold · 3 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 1 traceable claims on JNJ · showing the highest-conviction voices
“J&J's ~$3B buy of phase-one Halda (HLD-0915 oral 'hold-and-kill' prostate drug) is attractive, fits its prostate franchise and offsets upcoming patent expiries.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Johnson & Johnson (NYSE: JNJ) is a ~140-year-old diversified healthcare company that, since spinning off its Consumer Health business (Kenvue) in 2023, operates two segments: Innovative Medicine (branded pharmaceuticals) and MedTech (medical devices). Fiscal year ends late December.
Revenue mix (FY2025, from filings):
By segment: Innovative Medicine $60.40B (64%) · MedTech $33.79B (36%). Innovative Medicine spans immunology (Tremfya, Stelara), oncology (Darzalex, Carvykti, Erleada, Rybrevant), neuroscience (Spravato, Caplyta), cardiovascular/metabolism and pulmonary hypertension. MedTech spans cardiovascular (Abiomed, Shockwave, electrophysiology), orthopaedics, surgery and vision (Tecnis).
By geography: United States $53.75B (57%) · Europe $21.54B (23%) · Asia-Pacific/Africa $14.03B (15%) · Western Hemisphere ex-US $4.88B (5%). More US-weighted than a decade ago, which is both a pricing-power strength and a US-drug-policy exposure (§11).
The strategic story management keeps pressing is a "path to double-digit growth by the end of the decade" built on new approvals (icotrokinra/ICOTYDE oral psoriasis pill, Tremfya expansion, Darzalex quad regimens, Varipulse/Shockwave in cardiovascular) replacing the STELARA biosimilar cliff that is dragging Immunology now.
2. The expert thesis (traceable)
Synthos KB coverage of JNJ is thin: 1 traceable claim, 1 net-bullish voice, net conviction +72. This is a fundamentals- and quant-driven note, not a high-breadth conviction call — and we say so plainly rather than manufacture a panel.
The one voice — a targeted, bolt-on M&A thesis. Biotech Hangout (biotech_hangout-Tl-PuU9SrwU:c7beac507e, bullish, conviction 72, skill 1.0, dated 2025-11-21): J&J's ~$3B acquisition of phase-one Halda Therapeutics (HLD-0915, an oral "hold-and-kill" prostate-cancer drug) is attractive — it fits the existing prostate franchise (Erleada) and helps offset upcoming patent expiries. That is exactly the right frame for JNJ: the company grows by disciplined tuck-in dealmaking to replace maturing molecules, and this is one credible example.
Honest composite note. One claim is not a mandate. There is no cautionary voice in the KB to balance it, and no independent corroboration of the broader franchise. The bull/base/bear below therefore rests on the fundamentals and the estimate set, with the Halda claim as a single illustrative data point on the "M&A replaces the pipeline" mechanism — not as the pillar of the call.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Below-average risk
Net-debt/EBITDA 1.0×, beta 0.26, 69% gross margin and a Dividend-King payout make it about as sturdy as equities get — but 30× trailing after a +69% run, plus the unresolved talc litigation tail, keep it from a 2–3.
Mid-single-digit growth with no acceleration at a $633B cap. A great compounder, structurally incapable of a multibag from here.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
Case
Key assumptions
Fair value
Bull
Stelara erosion troughs early; Tremfya + oncology (Darzalex, Carvykti, Rybrevant) + cardiovascular (Shockwave, Abiomed) drive the "double-digit by decade-end" ramp; a talc settlement removes the overhang. FY27E EPS ~$13.0 (top of range) earns a re-rated ~23×.
~$300 (+14%)
Base(our anchor)
Estimates roughly hit — FY26E adj EPS $11.58, FY27E $12.76; a low-beta ~10%-EPS-compounder with a fortress sheet holds a ~20× forward multiple on FY27E.
~$258 (−2%)
Bear
Talc liability re-inflates; Stelara/biosimilar erosion runs deeper and a MedTech miss compounds it; multiple de-rates to ~17× on FY27E EPS shaded to ~$12.
~$205 (−22%)
Synthos fair value = the base case, ~$258 (−2%), with the full $205–$300 span as the honest range. This anchor sits essentially on top of the Street's $253 consensus — for once we and the sell-side agree that the stock is close to fairly valued here. That agreement, plus an RSI of 71 at an all-time high, is why the verdict is Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). JNJ is a textbook compounder with essentially zero exponential character:
Forward growth: revenue CAGR FY25→FY30E ~7.1% ($94.2B → $133.0B est); EPS CAGR ~9.7% (GAAP $11.03 → $17.52 est), a touch faster than sales as margins and buybacks help.
Acceleration (the 2nd derivative) is roughly flat-to-slightly-positive, not inflecting: management's own framing is a gradual build toward "double-digit growth by the end of the decade" — i.e. acceleration is a hoped-for 2028+ event, not something visible in the current ~6–7% operational print. No GLP-1-style inflection here.
Room to run: at $633B the law of large numbers is decisive. A 3× from here implies a ~$1.9T company; JNJ's diversified drug+device TAM is huge but it already owns a mature slice of it. Demand runway is not the constraint — scale is.
Reinvestment runway: ample and disciplined — ~$4.8B capex, ~$14.7B R&D, ~$17.5B of acquisitions in FY25 — but deployed to defend and refresh a mature base, not to compound a young franchise.
Exponential Potential: Low (2/10). Own JNJ for ballast, dividends and ~10% total-return compounding — not for a fast multibagger. This honest framing is exactly why it is not a flagship next-exponential.
Segments (FY25): Innovative Medicine $60.40B (+6.0% YoY), MedTech $33.79B (+6.1% YoY) — both growing in line.
Quarterly trajectory: Q1'25 $21.89B → Q2 $23.74B → Q3 $23.99B → Q4 $24.56B → Q1'26 $24.06B (+9.9% YoY reported, +6.4% operational). Healthy, but the Q1'26 GAAP EPS of $2.14 was down 52% YoY — because Q1'25 carried a large one-time gain (litigation/other); adjusted EPS was $2.70 vs $2.77, roughly flat — read the adjusted line, not the GAAP optics.
Margins: gross 69.1% TTM, EBITDA 34.8% TTM, net 21.8% TTM. Best-in-class for a diversified healthcare major.
Earnings: GAAP net income $26.80B FY25 (vs $14.07B FY24, which was depressed by talc/IPR&D charges); GAAP EPS $11.03. TTM net income per share $8.60.
Returns on capital:ROE 26.3%, ROIC 13.6%, ROA 10.5% — durable, well above cost of capital.
Balance sheet: total debt $47.9B, cash $19.7B, net debt $28.2B, net-debt/EBITDA ~1.0× — one of the strongest balance sheets in the S&P 500 (AAA-caliber). Interest coverage ~25×.
6. Valuation — priced in or room?
JNJ is not cheap after the run, but not egregious either. Trailing: 30.3× EPS, 6.9× EV/sales, 19.9× EV/EBITDA, ~7.9× book. The forward path compresses as EPS grows: 22.7× FY26E → 20.6× FY27E → 17.9× FY28E → 15.0× FY30E on consensus. A reverse read: at $263 the market prices roughly the Street's ~7% revenue / ~10% EPS CAGR plus the fortress/low-beta premium — i.e. fairly valued for a low-risk compounder, with little embedded upside and modest embedded downside cushion from the dividend (~2.0% yield) and buyback. The FMP letter rating is B+ (weak marks on P/E and debt-to-equity offsetting elite ROE/ROA). Street targets (context): consensus $253.42, high $283, low $208, median $260 — our $258 base FV sits right in the middle. This is a quality-at-fair-value name, not a value buy and not a screaming short.
7. Technicals (from the tech block)
Trend:up, and extended. $263 sits above the 50-DMA ($232.74) and 200-DMA ($218.94), 50 above 200 (golden-cross posture). MACD +6.97 (positive).
Location:exactly at the 52-week high ($263.04) — 0.0% off peak, +69.5% off the 52-week low ($155.17). Zero drawdown from the top, which cuts both ways: leadership, but no margin of safety on entry.
Momentum: RSI(14) 71.0 — above 70, i.e. overbought. A stretched-entry warning; buying at the print risks a near-term pullback.
Relative strength: JNJ +68.7% 12-mo vs SPY +20.6% and QQQ +30.3%; +7.8% 3-mo (lagging SPY +13.7% and QQQ +22.0% short-term as the rally matures). A big-cap defensive that dramatically outran the market over a year but is cooling off recently.
Read: technicals say don't chase the high. The best-risk-reward add is a pullback toward the rising 50-DMA (~$233) or lower, where RSI resets — consistent with the Watch verdict.
8. Moat & competitive position
JNJ's moat is breadth + durability rather than a single blockbuster. (1) Diversification: two large segments and dozens of products, so no single patent cliff is fatal — the classic defensive quality. (2) Scale in R&D and manufacturing: ~$14.7B annual R&D and a global commercial footprint few can match. (3) Balance-sheet firepower: a AAA-caliber sheet lets it out-acquire smaller rivals (the Halda, Shockwave, Abiomed deals). The trade-off is the flip side of diversification — no single franchise grows fast enough to move the $94B needle sharply, which is why growth is structurally mid-single-digit. Key competitive pressures: STELARA biosimilar erosion (already a ~9-point drag on Immunology growth per the Q1'26 release), oncology competition, and device-cycle competition in MedTech.
Peer set (market cap): Novartis $305B, Merck $320B, AstraZeneca $303B, AbbVie $461B, Amgen $202B, Gilead $163B, Pfizer $139B, Sanofi $104B, Novo Nordisk $224B, UnitedHealth $386B. At $633B JNJ is the largest of the diversified-pharma comps and trades at a premium multiple (30× vs many peers in the low-to-mid teens) — the market pays up for its diversification and balance-sheet safety.
9. Management, capital allocation & guidance
Capital allocation: balanced and shareholder-friendly — ~$12.4B dividends (a Dividend King, 60+ years of increases; ~$5.24/sh, ~2.0% yield), ~$6.0B buybacks, ~$17.5B of acquisitions, ~$4.8B capex in FY25, all funded from ~$20B FCF while holding net-debt/EBITDA ~1.0×. Textbook mature-compounder discipline.
Insider activity: routine — an EVP exercised options and sold 10,000 shares at ~$241 in June 2026 (Rule-10b5-1-style), an R&D EVP had a vest/withhold, and directors received deferred-share-unit awards. No alarming discretionary selling cluster in the sampled window.
Management's own guidance (the earnings-call track — half-weighted, they talk their book): the Q1'26 8-K (2026-04-14) is a real earnings release and JNJ raised 2026 guidance: estimated reported sales ~$100.8B mid-point (+7.0%), operational sales ~$100.2B mid (+6.4%), and adjusted EPS $11.55 mid-point (+7.1%) (range $11.45–$11.65). Management frames 2026 as "a year of accelerated growth" and reiterates a "path to double-digit growth by the end of the decade," citing new approvals (ICOTYDE oral psoriasis pill, Tecvayli+Darzalex Faspro in myeloma, Varipulse Pro, Tecnis PureSee). An Enterprise Business Review is set for December 8, 2026. Treat as self-interested but concrete; the raised outlook is a genuine positive data point, half-weighted.
10. Catalysts & what to watch
Next earnings: 2026-07-15 (Q2'26; Street EPS $2.83, revenue ~$25.0B). Key lines: operational sales growth vs the ~6% pace, STELARA erosion trajectory, MedTech (Shockwave/Abiomed) momentum, and any guidance update.
Talc litigation: any comprehensive settlement or adverse ruling — the single biggest swing factor for the multiple (removes or re-inflates the overhang).
STELARA biosimilar cliff: how fast Tremfya + oncology + neuroscience (Caplyta) offset it — the crux of the "double-digit by decade-end" story.
New launches: ICOTYDE (oral psoriasis), Rybrevant/Lazcluze in lung, Carvykti/Darzalex ramps, cardiovascular (Shockwave, Varipulse) — the growth insurance.
December 8, 2026 Enterprise Business Review: management's medium-term framing event.
Thesis tripwires (what would change the call): a talc liability re-inflation or adverse verdict; operational growth slipping below ~4%; adjusted EPS guidance cut; or a MedTech share-loss signal. Conversely, a talc settlement + a pullback toward the 50-DMA would flip this from Watch to Buy — Core.
11. Key risks
Talc litigation (structural, hard to quantify): the decades-old baby-powder liability is not fully resolved; a re-inflation of the reserve or an adverse mass-tort outcome is the classic JNJ tail-risk and the main reason a fortress balance sheet still scores a 4 not a 2.
STELARA biosimilar erosion: already a ~9-point drag on Immunology operational growth (Q1'26 release) — the near-term earnings headwind.
Valuation / de-rating: 30× trailing at an all-time high, RSI 71 — little margin for a growth or litigation disappointment.
US drug-pricing policy: 57% US revenue → exposed to IRA price negotiation, tariffs and PBM/formulary friction.
Thin expert coverage: only 1 KB claim — the Synthos conviction signal is weak, so this call leans harder on fundamentals/quant than on a panel.
12. Verdict, position sizing & monitoring
Watch. Johnson & Johnson is one of the highest-quality, lowest-risk businesses in the S&P 500 — fortress balance sheet (net-debt/EBITDA 1.0×, beta 0.26), 69% gross margin, 26% ROE, ~$20B FCF, a Dividend King payout, a raised 2026 outlook, and a diversified moat that no single patent cliff can sink. But at $263 — 30× trailing, 22.7× forward, at the 52-week high with RSI 71 — the price already reflects that quality, and our $258 base fair value sits essentially on the Street's $253 consensus with only mid-single-digit growth behind it. There is no margin of safety to chase here.
Sizing: if owned, defensive ballast, ~1–3% — a bond-proxy compounder for stability and income, not a growth engine. Prefer to add on weakness toward the rising 50-DMA (~$233) rather than at the high.
Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print and on any talc development. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $263.04.
Single biggest risk: the talc litigation tail combined with STELARA biosimilar erosion — the two things that could turn a "fairly valued" fortress into a de-rating.
Provenance & disclosures
Traceability: 1 KB claim, breadth 1, top skill 1.0 (Biotech Hangout), last claim 2025-11-21 — reconciled to a real claim_id (biotech_hangout-Tl-PuU9SrwU:c7beac507e), cited inline. Fabricated conviction is structurally impossible (claim-ID reconciliation); coverage here is thin and the note says so.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claim 2025-11-21. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: JNJ's raised 2026 guidance is management's own book (SEC 8-K, 2026-04-14), half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").